Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13558668 | 0.84 | NPC1 (0.51) | SMN1; SMN2NPC1RAB9AMAPK1MAPT | |
| SCHEMBL13558667 | 0.82 | NPC1 (0.59) | SMN1; SMN2NPC1RAB9AMAPK1MAPT | |
| SCHEMBL18124438 | 0.81 | NPC1 (0.49) | SMN1; SMN2NPC1RAB9AMAPK1MAPT | |
| SCHEMBL9778887 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AMAPK1MAPT | |
| SCHEMBL9778599 | 0.80 | RAB9A (0.48) | SMN1; SMN2NPC1RAB9AMAPK1MAPT | |
| SCHEMBL18119744 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AMAPK1MAPT | |
| SCHEMBL18124437 | 0.78 | OPRM1 (0.53) | SMN1; SMN2NPC1RAB9AMAPTLMNA | |
| SCHEMBL10144993 | 0.77 | NPC1 (0.43) | SMN1; SMN2NPC1RAB9AMAPK1MAPT | |
| SCHEMBL19923130 | 0.76 | NPC1 (0.42) | SMN1; SMN2NPC1RAB9AROR1 | |
| SCHEMBL10106364 | 0.74 | NPC1 (0.49) | SMN1; SMN2NPC1RAB9AMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018045142-A1 | IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018045142-A1 | IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180065917-A1 | IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS, INC. (JP) | 2018-03-08 | — | — | US | disclosed |
| US-20180065917-A1 | IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS, INC. (JP) | 2018-03-08 | — | — | US | disclosed |
| US-20180065917-A1 | IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS, INC. (JP) | 2018-03-08 | — | — | US | disclosed |
| US-9321739-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-8962667-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | Microdose Therapeutix, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8846735-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | MICRODOSE THERAPEUTX, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8119672-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | RYS DAVID J (US) | 2011-12-15 | — | — | US | disclosed |
| US-20050288345-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1545513-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1539691-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014317-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014316-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2002059132-A1 | INTERMEDIATE COMPOUNDS USEFUL FOR MAKING ANTIVIRAL COMPOUNDS | VIROPHARMA INCORPORATED (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, PML | SMN1; SMN2 1044/4885NPC1 215/4885RAB9A 2880/4885 |
| US-20050288345-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | TTPA, HAVCR2, PML | SMN1; SMN2 1044/4885NPC1 215/4885RAB9A 2880/4885 |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | TTPA, HAVCR2, ZC3HAV1 | SMN1; SMN2 1129/4885NPC1 223/4885RAB9A 2841/4885 |
| US-20140072532-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | SMN1; SMN2 1129/4885NPC1 223/4885RAB9A 2841/4885 |
| US-20180065917-A1 | IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CD274, PDCD1, PDCD1LG2 | SMN1; SMN2 769/4885NPC1 1942/4885RAB9A 2168/4885 |
| US-20140363395-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | SMN1; SMN2 1129/4885NPC1 223/4885RAB9A 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.